(Q35989717)

11 August 2017

1 reference

title

Adjuvant chemotherapy for primary breast cancer (English)

1 reference

11 August 2017

1 reference

Monica Fornier

1

1 reference

11 August 2017

Clifford Hudis

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

published in

Current Oncology Reports

1 reference

11 August 2017

volume

7

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

18-22

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-005-0021-1

11 August 2017

exact match

0 references

cites work

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy

1 reference

12 December 2020

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

12 December 2020

Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results

1 reference

12 December 2020

A Gompertzian model of human breast cancer growth.

1 reference

12 December 2020

High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.

1 reference

12 December 2020

Cancer statistics, 2004

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

12 December 2020

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

12 December 2020

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

12 December 2020

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

1 reference

12 December 2020

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

12 December 2020

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

12 December 2020

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

12 December 2020

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

12 December 2020

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study

1 reference

12 December 2020

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

1 reference

12 December 2020

10.1007/S11912-005-0021-1

Identifiers

DOI

1 reference

11 August 2017

1 reference